Business Wire

Cepton Introduces the World’s Smallest Wide Field of View Lidar Sensor for Near-Range Applications

Share

Cepton Technologies, Inc., a leading provider of state-of-the-art, intelligent, lidar-based solutions, has announced its path-breaking miniature lidar sensor – the Nova - priced at less than $100 for high volume automotive applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005035/en/

With a lidar target size of 3.5 cm (W) x 3.5 cm (H) x 7.5 cm (D), and weighing less than 350 g, the Nova is extremely compact and easily embeddable for automotive applications. © 2021 Cepton Technologies.

With a lidar target size of 3.5 cm (W) x 3.5 cm (H) x 7.5 cm (D), and weighing less than 350 g, the Nova is extremely compact and easily embeddable for automotive applications. © 2021 Cepton Technologies.

The Nova is a wide angle near-range lidar sensor intended to address major gaps in proximity detection of objects with current sensor technologies. Featuring best-in-class, high resolution 3D imaging with a high field of view (FOV) of 90-120° (H) and 60-90° (V), depending on configuration, Nova sets a worldwide benchmark with its unprecedented combination of compactness, FOV coverage and affordability.

Powered by Cepton’s patented and proven Micro Motion Technology (MMT®), the non-rotational, mirrorless, and frictionless Nova lidar can be hidden all around a vehicle to provide a complete 360° view of its immediate surroundings. With a lidar target size of 3.5 cm (W) x 3.5 cm (H) x 7.5 cm (D), and weighing less than 350 g, the ultra-small Nova is an easily embeddable lidar sensor that not only enables optimal styling choices but demonstrates the scalability of MMT® to the smallest form factors.

Nova has an angular resolution of up to 0.3°, with a maximum range of up to 30 m and is therefore ideal for automotive Advanced Driver Assistance Systems (ADAS) and autonomous vehicle (AV) applications such as blind spot detection, small object detection, automated park assist and free space estimation around the vehicle. For vehicles, a multi-lidar architecture can be facilitated, thereby creating a virtual safety zone all around while minimizing disruption to vehicle design aesthetics.

Nova is ideally suited for accurate detection of objects in proximity, such as small children, on-road objects, road edges, stationary objects and more. With this level of capability and its ultra-compact design, Nova can not only support ADAS and AV applications but also autonomous ground vehicle (AGV) and smart industrial applications.

With lidar’s increasing presence in cars and trucks, Cepton has been innovating its technology to meet the stringent requirements from OEMs and Tier 1s while striving to advance lidar designs that enable easy integration in the next generation of automobiles. Nova is the latest representation of Cepton’s state-of-the-art lidar innovation, that encompasses the goal of automotive-grade reliability, low power (<3.5 W) and high performance, along with an elegant, minimalistic design that requires only small amounts of real estate in the vehicle body.

Nova’s modular design and easily accessible components make it highly manufacturable, with very low cost at high volume. Previously, Cepton was one of the first in the industry to announce a <$1,000 volume lidar price for high performance, long range lidar (Vista-X90). Consistent with that trend, Nova is the first high field of view, near-range lidar with a <$100 price point for high automotive volumes. This fulfils Cepton’s objective to bring to market scalable, mass-market lidar solutions that enable the automotive industry to substantially accelerate safety and autonomy innovations in the next generation of vehicles.

“The Nova is an industry-first, transformational lidar that fundamentally changes the game for near-field sensing,” said Cepton CEO Dr. Jun Pei. “Currently, consumer vehicles have been limited to technologies that cannot facilitate true Level 3 or Level 4 autonomy for the mass market. Radars, cameras and ultrasonic sensors suffer from high false positives and false negatives. Rotational lidars are not embeddable, making them impractical for consumer vehicles. Near-range flash lidars either lack the wide field of view or cannot match the power and size requirements to be discretely hidden all around the vehicle. The Nova represents path-breaking lidar innovation for the automotive industry in that it achieves a level of performance that is unmatched for such a small form factor.”

Nova is targeted for high volume production starting in 2023. Due to anticipated high demand for samples, Nova will only be available to select customers in 2021 through Cepton’s Early Access Program. If you would like to be part of this program or would like more details, please contact Mitch Hourtienne, Cepton Senior Director of Business Development at mitch.hourtienne@cepton.com.

To learn more about the Nova and Cepton’s automotive grade lidar capabilities, join Cepton at the upcoming digital CES 2021, from January 11th to 14th, via our virtual booth page (CES registration required). On Jan 12th, Cepton CMO, Dr. T. R. Ramachandran will join North American Lighting (NAL) for a virtual panel discussion on “Impact of Sensors on Mobility” at 11 a.m. (PST) and present at an online NAL-hosted webinar “Lidar, What’s the Future?” at 2 p.m. (PST). Watch the online sessions for free to learn more about how lidar is transforming the world and how Cepton’s smart lidar solutions are ideally suited for automotive and smart infrastructure applications.

About Cepton Technologies, Inc.

Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.

Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn.

Contact information

Faithy Li, Cepton Technologies, media@cepton.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF ® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy16.1.2021 22:15:00 CETPress release

Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine + bevacizumab (C-B) in a first-line setting for patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy.1 The data were announced today during an oral presentation at the 2021 ASCO Gastrointestinal Cancers Symposium (ASCO-GI). Patients with mCRC who are not eligible for chemotherapy face a large unmet need, with fewer treatment options available to them and lower survival rates. Colorectal cancer (CRC) makes up 9.7% of total global cancer cases, with almost 1.4 million new cases of CRC each year.2 In Europe, CRC is the second most common cause of death due to cancer, and those with a metastatic disease have a 5-year survival rate of just 11%.3 “For patients with metastatic colorectal cancer, those non-eligible for standard combination therapy have few options left and we are conti

H.I.G. Realty Invests in Production Studios & Content Hub in Madrid15.1.2021 09:00:00 CETPress release

H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with $43 billion of equity capital under management, announced today that one of its affiliates has invested in Madrid Content City, an approximately 140,000 square meter hub with state of the art audio-visual facilities, including production studios, production & post-production technical facilities, and a university focused on media studies. H.I.G. continues to add to its sizeable portfolio of real estate assets across Europe, consisting of both equity as well as debt investments, with a particular focus on its target market of value-added small and midcap opportunities. Riccardo Dallolio, Managing Director and Head of H.I.G. Europe Realty Partners, commented: “Madrid Content City will benefit from strong secular tailwinds underpinned by the boom in content production. The state-of-the-art studios and related facilities, the exceptional multinational tenant line-up with long term leases, and its critical mas

Eurofins, the global leader in analytical testing, expands worldwide face mask testing & certification capabilities15.1.2021 07:30:00 CETPress release

Since the start of the pandemic Eurofins (Paris:ERF) has tested thousands of models of surgical and hygienic masks and provided best-in-class speed and certification for PPEs globally, enabling these critical products to get market as fast as possible. Eurofins has developed global leading testing capabilities and certification services in the North America, Europe and Asia ensuring that PPE manufacturers are able to provide the indispensable support needed in the fight against the coronavirus. As of today, Eurofins is one of the few GLP certified and ISO/IEC 17025 accredited laboratory networks to fully cover all testing requirements for surgical/medical and hygienic masks by the FDA, EU regulations and many international and country-specific directives and guidelines such as CEN, CE Marking, ISO, ASTM or OECD. Our robust portfolio for masks includes globally accepted, safety and performance testing, virucidal, bacterial filtration, particle filtration, differential pressure, biocompa

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport ® (abobotulinumtoxinA) in five therapeutic indications15.1.2021 07:00:00 CETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced results from new analyses of pivotal Phase III clinical trial data to assess treatment intervals over repeat cycles of Dysport® (abobotulinumtoxinA [aboBoNT-A]) in five patient populations. AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations is being shared during the TOXINS 2021 conference, which is taking place virtually between 16-17 January 2020 and is organized by the International Neurotoxin Association.1-28 Ipsen is sharing 26 abstracts during the congress, with data including updates from the recently published surveys into the experience of patients and caregivers, data from the Phase IV ULIS-III trial, and ten abstracts focused on basic science research into neurotoxins.1-27 Spasticity is one of the most common and disabling conditions associated with many neurological conditions in adults and is characterized by velocity-dependent muscle hypertonia. Spasticity can lead to disabilit

Velodyne Lidar Commends NHTSA Plan to Update NCAP14.1.2021 21:58:00 CETPress release

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today commended the U.S. Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) plan to update to its New Car Assessment Program (NCAP). The NHTSA proposal would add four advanced driver assistance system (ADAS) capabilities to the NCAP, keeping pace with evolving safety technologies and providing much-needed information to consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005992/en/ Images show vehicle with lidar-based PAEB stopping before adult target @ 50% overlap (above) and vehicle with camera and radar-based PAEB crashing into adult target (below). (Photo: Velodyne Lidar, Inc.) NCAP is the U.S. Government’s premier consumer information program for evaluating vehicle safety performance. The NHTSA proposal to add ADAS technologies to the NCAP includes pedestrian automatic emergency braking, lane keeping support, blind spot warning and

Snow Software Recognized as a 2020 Gartner Peer Insights Customers’ Choice for Software Asset Management14.1.2021 20:39:00 CETPress release

Snow Software, the global leader in technology intelligence, today announced that the company was named a December 2020 Gartner Peer Insights Customers’ Choice for Software Asset Management (SAM) Tools. Gartner defines software asset management tools as technology that “automates many of the tasks required to maintain compliance with software licenses, thereby controlling software spending.” This is the fourth Gartner Peer Insights Customers’ Choice announcement for SAM, and Snow has earned the distinction all four times. Based solely on feedback from verified customers, Gartner Peer Insights Customers’ Choice reflects reviews and ratings published within the last 12 months. Snow received 100 reviews – the most of any vendor in the market – with an overall rating of 4.6 out of 5 as of January 12, 2021. Earlier this year, Snow was recognized as a Leader in Gartner’s 2020 Magic Quadrant for Software Asset Management Tools1 and received the highest scores in three out of four use cases in

Veristat Supported Marketing Applications for 10% of All FDA Novel Drug Approvals in 202014.1.2021 19:15:00 CETPress release

Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of the 2020 US Food and Drug Administration (FDA) novel drug approvals. The FDA approved 53 novel drugs, defined by the FDA as New Molecular Entities (NMEs)i, and Veristat regulatory, statistical, and medical writing experts were integral in preparing five of these NME New Drug Applications. Veristat also prepared NDA/BLAs for three non-NME FDA approvals and one Marketing Authorization Application (MAA) that received approval in Europe. "Despite the global challenges in 2020, Veristat continued to advance its mission of helping clients achieve regulatory approval of novel medical therapies," stated Patrick Flanagan, Chief Executive Officer at Veristat. "Now, more than ever, Veristat is focused on providing expert guidance to facilitate the rapid approval for therapies that improve the lives of patients and their families around the world." Ve

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom